Corporate News  |  03. September 2018

MagForce AG to participate in nine upcoming international conferences in H2 2018

**Berlin, Germany and Nevada, USA, September 3, 2018** - MagForce AG (Frankfurt, Scale, Xetra: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, today announced its participation in nine upcoming scientific and investor conferences in the second half of 2018:

- **German Fall Conference**  
  Date: September 3-4, 2018  
  Location: Frankfurt, Germany  
  Presentation: Christian von Volkmann, CFO of MagForce AG, Tuesday, September 4, 2018

- **Goldman Sachs European Medtech and Healthcare Conference**  
  Date: September 5-6, 2018  
  Location: London, UK  
  Presentation: Ben J. Lipps, CEO of MagForce AG, Thursday, September 6, 2018

- **Berenberg & Goldman Sachs Seventh German Corporate Conference**  
  Date: September 24-26, 2018  
  Location: Munich, Germany  
  Presentation: Ben J. Lipps, CEO of MagForce AG, Tuesday, September 25, 2018

- **13th Meeting of the European Association of Neuro-Oncology (EANO 2018)**  
  Date: October 10-14, 2018  
  Location: Stockholm, Sweden

- **18th European Congress of Neurosurgery (EANS 2018)**  
  Date: October 21-25, 2018  
  Location: Brussels, Belgium  
  Booth: No. 12  
  Lunch Symposium: “Local Therapies For Malignant Gliomas”  
  Speakers: Prof Dr Walter Stummer, Director of the Department of Neurosurgery at the University Hospital Muenster, Germany; Colin Watts, MD PHD, University of Birmingham, Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, Birmingham, Great Britain  
  Date & Time: Golden Hall, Tuesday, October 23, 2018; 1.15-2.15pm CEST
• MEDICA 2018  
  Date: November 12-15, 2018  
  Location: Düsseldorf, Germany  
  Community booth: Berlin Partner für Wirtschaft und Technologie GmbH No. F 42, hall 15

• 23rd Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology (SNO)  
  Date: November 15-18, 2018  
  Location: New Orleans, Louisiana, USA

• German Equity Forum 2018  
  Date: November 26-28, 2018  
  Location: Frankfurt, Germany  
  Presentation: Ben J. Lipps, CEO of MagForce AG, Tuesday, November 27, 2018

• Prior Capital Market Conference  
  Date: December 4, 2018  
  Location: Dreieich, Germany  
  Presentation: Barbara von Frankenberg, Vice President Communications & Investor Relations of MagForce AG, Tuesday, December 4, 2018

About MagForce AG and MagForce USA, Inc.  

MagForce AG, listed in the Scale segment of the Frankfurt Stock Exchange (MF6, ISIN: DE000A0HGQF5), together with its subsidiary MagForce USA, Inc. is a leading medical device company in the field of nanomedicine focused on oncology. The Group's proprietary NanoTherm® therapy enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of superparamagnetic nanoparticles.

NanoTherm®, NanoPlan®, and NanoActivator® are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm, NanoPlan, and NanoActivator are trademarks of MagForce AG in selected countries.

Disclaimer

This release may contain forward-looking statements and information which may be identified by formulations using terms such as "expects", "aims", "anticipates", "intends", "plans", "believes", "seeks", "estimates" or "will". Such forward-looking statements are based on our current expectations and certain assumptions, which may be subject to a variety of risks and uncertainties. The results actually achieved by MagForce AG may
substantially differ from these forward-looking statements. MagForce AG assumes no obligation to update these forward-looking statements or to correct them in case of developments, which differ from those, anticipated.